Download PDF
Open Access
CC BY 4.0 · TH Open 2019; 03(02): e157-e164
DOI: 10.1055/s-0039-1692202
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Type 2 Valvular Heart Disease Affects Decision Making for Anticoagulation in Patients with Atrial Fibrillation: The UMBRIA-Fibrillazione Atriale Prospective Study

Authors

  • Maria Cristina Vedovati

    1   Vascular and Emergency Medicine - Stroke Unit, University of Perugia, Perugia, Italy

  • Gianpaolo Reboldi

    2   Department of Medicine, University of Perugia, Perugia, Italy

  • Giancarlo Agnelli

    1   Vascular and Emergency Medicine - Stroke Unit, University of Perugia, Perugia, Italy

  • Paolo Verdecchia

    3   Fondazione Umbra Cuore e Ipertensione-ONLUS, Ospedale S. Maria Della Misericordia, Perugia, Italy
    • on Behalf of the Umbria-Fibrillazione Atriale Investigators

Funding Supported in part from the no-profit “Fondazione Umbria Cuore e Ipertensione-ONLUS,” Perugia, Italy.
Further Information

Publication History

18 September 2018

24 April 2019

Publication Date:
05 June 2019 (online)

Also available at
  Permissions and Reprints

Abstract

Background Valvular heart disease (VHD) and atrial fibrillation (AF) often coexist.

Aim We investigated whether type 2 VHD (other than moderate-severe rheumatic mitral stenosis or mechanical heart valve) influences the prescription of anticoagulants in AF.

Methods Umbria-Fibrillazione Atriale is a prospective multicenter registry in patients with AF. For the purpose of this study, type 2 VHD patients were propensity matched with non-VHD counterparts in a 1:1 ratio. Patients with type 1 VHD (moderate-severe mitral stenosis or mechanical heart valve) were excluded.

Results We identified 2,212 patients with AF and excluded 46 because data on VHD were unavailable. Type 2 VHD was present in 426 patients (19.7%). Before registry entry visit, 77.1% of type 2 VHD and 66.8% of non-VHD patients were on anticoagulants. At discharge, 90.8 and 85.2% of patients, respectively, were on anticoagulants. After propensity-score matching, 386 patient-pairs were created. In the matched sample, the likelihood of being on anticoagulants before (odds ratio [OR]: 1.43, 95% confidence interval [CI]: 1.02–2.01, p = 0.036) and after (1.63, 95% CI: 1.04–2.57, p = 0.034) the entry visit was higher in type 2 VHD than in non-VHD patients. Patients with type 2 VHD were 70% more likely to receive vitamin K antagonists (VKAs) (OR: 1.70, 95% CI: 1.28–2.27, p < 0.001), and 32% less likely to receive non–vitamin K oral anticoagulants (NOACs; OR: 0.68, 95% CI: 049–0.94, p = 0.011) than non-VHD patients.

Conclusion VKAs consistently outperformed NOACs as preferred treatment option in patients with type 2 VHD. This could potentially deny to these patients the well-established benefits of NOACs observed in phase III trials.

Keywords

atrial fibrillation - valvular heart disease - vitamin K antagonists - non–vitamin K oral anticoagulants

Authors' Contributions

M.C.V. has made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; (3) final approval of the version to be submitted.


G.R. has made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; (3) final approval of the version to be submitted.


G.A. has made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; (3) final approval of the version to be submitted.


P.V. has made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; (3) final approval of the version to be submitted.


* Appendix A lists all the Umbria-Fibrillazione Atriale Investigators.